ReAlta Life Sciences Announces EMA Orphan Drug Designation for RLS-0071 for the Treatment of Neonatal Encephalopathy

Source :: Legal Monitor Worldwide. December 5, 2020
Publication Year :: 2020
Abstract: ReAlta Life Sciences, Inc., today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to RLS-0071 (also known as PIC1-dPEG24) for the treatment of neonatal encephalopathy. This [...]

Subjects :: United States. Food and Drug Administration
Encephalopathy -- Drug therapy
Newborn infants -- Drug therapy
Orphan drugs
Business, international
Law

Tools